Furthermore, in September 2020, atezolizumab plus bevacizumab therapy, a combination of an immune checkpoint inhibitor and anti-vascular endothelial growth factor (VEGF), was introduced as a first-line treatment option for u-HCC [6]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.